InflaRx is entering a critical phase with several upcoming catalysts:
Phase 3 interim results for vilobelimab in Pyoderma Gangrenosum (PG) are expected shortly. The program already has both Fast Track and Orphan Drug Designation from the FDA, which could enable accelerated approval if the data are strong.
Phase 2a results for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) are anticipated this summer. Both indications target large unmet medical needs and multi-billion-dollar markets.
Preclinical data for INF904 showed superior efficacy compared to Avacopan, which was acquired by Amgen for $3.7B.
InflaRx maintains a cash position of approximately $70M, suggesting the company is fully funded through these major milestones.
Guggenheim Securities has issued a $10 price target for IFRX, representing significant upside potential from current levels.
With multiple important readouts expected this year, IFRX could attract substantial attention if results are positive.
DYOR (Do Your Own Research)
Market Data 
Markets 
